Approving Psychedelics
The organization formed... as a public-benefit corporation, in anticipation that MDMA-assisted therapy would win FDA approval and start to reap taxable revenue that it couldn’t manage as a nonprofit.
Select Page
by C. Scott McMillin | May 13, 2024 | Addictive Substances | 0 |
The organization formed... as a public-benefit corporation, in anticipation that MDMA-assisted therapy would win FDA approval and start to reap taxable revenue that it couldn’t manage as a nonprofit.
by C. Scott McMillin | Feb 8, 2024 | Addictive Substances | 0 |
by C. Scott McMillin | Jan 29, 2024 | Addictive Substances | 0 |
by C. Scott McMillin | Jan 15, 2024 | Treatment | 0 |
by C. Scott McMillin | Dec 21, 2023 | Addictive Substances | 0 |
by C. Scott McMillin | Dec 18, 2023 | Treatment | 0 |
by C. Scott McMillin | Nov 27, 2023 | Addictive Substances | 0 |
Translation: the absence of adequate masking would presumably explain why ketamine appeared superior – due to an error in the study design.
Read Moreby C. Scott McMillin | Nov 9, 2023 | Addictive Substances | 0 |
Once again based on experience, I’m confident that many of the folks who will try psilocybin in future, because of all the favorable publicity, will fall into those ‘excluded’ categories.
Read Moreby C. Scott McMillin | Nov 2, 2023 | Public Health | 0 |
CDC claims that 1 in 5 drug overdoses in 2020 – or 20% — involved people in those two sectors alone. Something to think about.
Read Moreby C. Scott McMillin | Oct 19, 2023 | Addictive Substances | 0 |
And if there were damage, it’d be our brains that were affected, right? The very organ we’re asking now to evaluate its own functioning. It’s not a happy thought.
Read Moreby C. Scott McMillin | Aug 21, 2023 | Addictive Substances | 0 |
Many potential customers for psychedelic assisted therapy view the trip as a barrier. They’d rather not face the risks inherent in such an experience.
Read Moreby C. Scott McMillin | Jul 27, 2023 | Addictive Substances | 0 |
…the research team said their finding “raises serious questions about the use of opioid therapy for acute low back and neck pain.” Such as, why risk it? If it isn’t effective, and for some, can make things worse.
Read Moreby C. Scott McMillin | Jul 17, 2023 | Addiction | 1 |
An estimate of today’s CUD population in the US: 14.2 million persons.
Read Moreby C. Scott McMillin | Jul 13, 2023 | Addictive Substances | 0 |
In 1961, two Harvard students ended up in the mental hospital after consuming psilocybin…” Not long afterwards, Harvard lost much of its enthusiasm for the (psilocybin research) program.
Read Moreby C. Scott McMillin | Jun 26, 2023 | Thinking About Addiction | 0 |
This in spite of the fact … that these drugs can and often do interact harmfully with one another. And regular users are at elevated risk for misuse, abuse, dependence, and/or addiction.
Read Moreby C. Scott McMillin | Jun 22, 2023 | Treatment | 0 |
There appears to be good evidence for relying on an extended taper off opioids versus a more rapid process. Instead of fast cessation of use, the opioid is deliberately reduced on a preset schedule.
Read Moreby C. Scott McMillin | Jun 15, 2023 | Addictive Substances | 0 |
From a treatment perspective, our goal has to be to provide patients with accurate information about cannabis use and its associated risks, so that their decisions will be informed ones.
Read Moreby C. Scott McMillin | Jun 1, 2023 | Addictive Substances | 0 |
Because studies also suggest some real risks. Dangers, in fact. It’s possible that the current wave of fawning reports of miraculous cures could be replaced by stories of horrific incidents.
Read More